Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #128010 on Biotech Values
genisi
10/08/11 2:18 PM
#128016 RE: jq1234 #128010
Perifosine in phase I with different dosing regimens as single agent, found no response in CRC. Thus this could be the drug finally found the right combination for right disease setting, or the drug worked in a trial for patients that have certain hidden characteristics/inbalance that cannot be repeated in large trial. I don't think anyone knows at this point.